From atopic dermatitis to contact dermatitis, discover expert-backed treatments and lifestyle changes that can help manage ...

In September 2021, the FDA approved Opzelura (ruxolitinib) for the treatment of mild to moderate atopic dermatitis. It is recommended for those whose symptoms do not properly respond to other topical ...

Biologic treatments are a new option for people with moderate to severe eczema or atopic dermatitis. Most people can control eczema with prevention techniques, topical treatments, or ultraviolet ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...

It was first approved in Aug. 2024 to treat patients with prurigo nodularis. The FDA has approved Galderma’s Nemluvio (nemolizumab) for the treatment of patients age 12 and older with moderate to ...

Opens in a new tab or window The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of moderate-to-severe atopic dermatitis, drugmaker Galderma ...

that is not controlled using topical prescription therapies alone. The drug has also just been recommended for both indications in the EU. Getting approval in atopic dermatitis is viewed as a key ...